[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100383658":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":38,"locations":48,"responsibleParty":227,"collaborators":229,"id":232,"slug":233,"hasResults":234,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":11,"eligibilityCriteria":238,"healthyVolunteers":234,"sex":239,"minAge":240,"maxAge":11,"enrollmentInfo":241,"targetDuration":11,"studyType":244,"phases":245,"briefSummary":247,"conditions":248,"keywords":251,"overallStatus":69,"whyStopped":11,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":263},{"fullName":5,"class":6},"Ascentage Pharma Group Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"APG-115\u002FAPG-115+Cytarabine in Relapse\u002FRefractory AML","EXPERIMENTAL",null,[13,14],"Drug: APG-115","Drug: Cytarabine",{"label":16,"type":10,"description":11,"interventionNames":17},"APG-115\u002FAPG-115+Aza in relapsed\u002Fprogressed high risk MDS",[13,18],"Drug: Azacitidine",[20,25,29],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","APG-115","APG-115 orally once daily from Days 1 to 7 every 28 days.",[16,9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Azacitidine","75 mg\u002Fm\\^2 SC QD on Days 1- 7 (28-day cycle)",[16],{"type":21,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"Cytarabine","1g\u002Fm\\^2 IV QD on Days 3-7 (28-day cycle)",[9],[34],{"name":35,"affiliation":36,"role":37},"Jianxiang Wang, M.D.","Blood Diseases Hospital Chinese Academy of Medical Sciences","PRINCIPAL_INVESTIGATOR",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":11,"email":43},"Junyuan Qi, M.D.","CONTACT","+86-18622662361","qi_jy@yahoo.com",{"name":45,"role":41,"phone":46,"phoneExt":11,"email":47},"Bo Jiang, M.D.","+86-22-23909067","jianbo044@163.com",[49,67,82,94,106,118,128,142,156,164,178,190,202,210],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"The First Hospital of Peking University","NOT_YET_RECRUITING","Beijing","Beijing Municipality","100034","China","CN",{"type":58,"coordinates":59},"Point",[60,61],116.39723,39.9075,{"lat":61,"lon":60},[64,66],{"name":65,"role":41,"phone":11,"phoneExt":11,"email":11},"Qian Jiang, Ph.D",{"name":65,"role":37,"phone":11,"phoneExt":11,"email":11},{"facility":68,"status":69,"city":70,"state":71,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Guangzhou panyu central hospital","RECRUITING","Guangzhou","Guangdong",{"type":58,"coordinates":73},[74,75],113.25,23.11667,{"lat":75,"lon":74},[78,80],{"name":79,"role":41,"phone":11,"phoneExt":11,"email":11},"Shuqin Cheng, Master",{"name":81,"role":41,"phone":11,"phoneExt":11,"email":11},"Hui Yang Professor",{"facility":83,"status":69,"city":70,"state":71,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":84,"geoPoint":86,"contacts":87},"Nanfang Hospital of Southern Medical University",{"type":58,"coordinates":85},[74,75],{"lat":75,"lon":74},[88,90],{"name":89,"role":41,"phone":11,"phoneExt":11,"email":11},"Yu Zhang, Master",{"name":91,"role":41,"phone":92,"phoneExt":11,"email":93},"Chongyuan Xu Professor","86-020-62786845","nfyygcp@126.com",{"facility":95,"status":69,"city":96,"state":97,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Henan Provincial Oncology Hospital","Zhengzhou","Henan",{"type":58,"coordinates":99},[100,101],113.64861,34.75778,{"lat":101,"lon":100},[104],{"name":105,"role":41,"phone":11,"phoneExt":11,"email":11},"Xudong Wei, M.D.",{"facility":107,"status":69,"city":108,"state":109,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"Union Hospital medical college Huazhong University of Science and Technology","Wuhan","Hubei",{"type":58,"coordinates":111},[112,113],114.26667,30.58333,{"lat":113,"lon":112},[116],{"name":117,"role":41,"phone":11,"phoneExt":11,"email":11},"Qiubo Li, Doctor",{"facility":119,"status":69,"city":108,"state":109,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":120,"geoPoint":122,"contacts":123},"Zhongnan Hospital of Wuhan University",{"type":58,"coordinates":121},[112,113],{"lat":113,"lon":112},[124,126],{"name":125,"role":41,"phone":11,"phoneExt":11,"email":11},"Fuling Zhou, M.D.",{"name":127,"role":41,"phone":11,"phoneExt":11,"email":11},"Jianying Huang Director",{"facility":129,"status":69,"city":130,"state":131,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"Xiangya Hospital Central South University","Changsha","Hunan",{"type":58,"coordinates":133},[134,135],112.97087,28.19874,{"lat":135,"lon":134},[138,140],{"name":139,"role":41,"phone":11,"phoneExt":11,"email":11},"Qun He, Master",{"name":141,"role":41,"phone":11,"phoneExt":11,"email":11},"Qun Qin, M.D.",{"facility":143,"status":51,"city":144,"state":145,"zip":146,"country":55,"countryCode":56,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"The First Affilated Hospital of Ganzhou Medical University","Suzhou","Jiangsu","215636",{"type":58,"coordinates":148},[149,150],120.59538,31.30408,{"lat":150,"lon":149},[153,155],{"name":154,"role":41,"phone":11,"phoneExt":11,"email":11},"Liping Liu, Ph.D.",{"name":154,"role":37,"phone":11,"phoneExt":11,"email":11},{"facility":157,"status":69,"city":144,"state":145,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":158,"geoPoint":160,"contacts":161},"The First affiliated hospital of Soochow University",{"type":58,"coordinates":159},[149,150],{"lat":150,"lon":149},[162],{"name":163,"role":41,"phone":11,"phoneExt":11,"email":11},"Xiaowen Tang, Doctor",{"facility":165,"status":51,"city":166,"state":167,"zip":168,"country":55,"countryCode":56,"cosmosGeoPoint":169,"geoPoint":173,"contacts":174},"The First Affiliated Hospital of Nanchang University","Nanchang","Jiangxi","330006",{"type":58,"coordinates":170},[171,172],115.85306,28.68396,{"lat":172,"lon":171},[175,177],{"name":176,"role":41,"phone":11,"phoneExt":11,"email":11},"Fei Li, Ph.D.",{"name":176,"role":37,"phone":11,"phoneExt":11,"email":11},{"facility":179,"status":69,"city":180,"state":181,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":182,"geoPoint":186,"contacts":187},"First Hospital of Jilin University","Changchun","Jilin",{"type":58,"coordinates":183},[184,185],125.32278,43.88,{"lat":185,"lon":184},[188],{"name":189,"role":41,"phone":11,"phoneExt":11,"email":11},"Sujun Gao, M.D.",{"facility":191,"status":69,"city":192,"state":193,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":194,"geoPoint":198,"contacts":199},"Shanghai Jiao Tong University school of medicine Ruijing Hospital","Shanghai","Shanghai Municipality",{"type":58,"coordinates":195},[196,197],121.45806,31.22222,{"lat":197,"lon":196},[200],{"name":201,"role":41,"phone":11,"phoneExt":11,"email":11},"Junmin Li Professor",{"facility":203,"status":69,"city":192,"state":193,"zip":11,"country":55,"countryCode":56,"cosmosGeoPoint":204,"geoPoint":206,"contacts":207},"Shanghai Sixth people's Hospital",{"type":58,"coordinates":205},[196,197],{"lat":197,"lon":196},[208],{"name":209,"role":41,"phone":11,"phoneExt":11,"email":11},"Chunkang Chang Professor",{"facility":36,"status":69,"city":211,"state":212,"zip":213,"country":55,"countryCode":56,"cosmosGeoPoint":214,"geoPoint":218,"contacts":219},"Tianjin","Tianjin Municipality","300020",{"type":58,"coordinates":215},[216,217],117.17667,39.14222,{"lat":217,"lon":216},[220,224],{"name":221,"role":41,"phone":222,"phoneExt":11,"email":223},"Jianxiang Wang, MD","+86 22-23909120","wangjx@ihcams.ac.cn",{"name":225,"role":41,"phone":226,"phoneExt":11,"email":43},"Junyuan Qi, MD","+86 18622662361",{"type":228,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[230],{"name":231,"class":6},"Suzhou Yasheng Pharmaceutical Co., Ltd.","100383658","phase-1-a-phase-ib-study-of-apg-115-single-agent-or-in-combination-with-azacitidine-or-cytarabine-in-patients-with-aml-and-mds-100383658",false,"NCT04275518","A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.","A Phase Ib Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of APG-115 as a Single Agent or in Combination With Azacitidine or Cytarabine in Patients With Relapse\u002FRefractory AML and Relapsed\u002FProgressed High\u002FVery High Risk MDS","Inclusion Criteria:\n\n1. Patients with a diagnosis of histologically confirmed relapsed or refractory (R\u002FR) acute myeloid leukemia by WHO classification or relapsed\u002Fprogressed high\u002Fvery high risk MDS (score≥4.5) according to IPSS-R risk stratification\n2. Age \\>\u002F= 18 years.\n3. Adequate organ function\n4. Subject must have a projected life expectancy of at least 12 weeks.\n5. ECOG performance status of 0-1.\n6. Patient must have the ability to understand the requirements of the study and signed informed consent. A signed informed consent by the patient or his legally authorized representative is required prior to their enrollment on the protocol.\n7. Subject has a white blood cell count\\\u003C 50 × 109\u002FL. Note: Hydroxyurea is permitted to meet this criterion.\n\nExclusion Criteria:\n\n1. Subject has acute promyelocytic leukemia.\n2. Patients must not have had leukemia biotherapy 4 weeks prior to starting investigational drug, or less than 5 half-lives small molecular targeted drug therapy, or 28 days any anti-cancer therapy (whichever is longer)\n3. Uncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure (NYHA Class III or IV), unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n4. Active infection requiring systemic antibiotic\u002Fantifungal medication, known clinically active hepatitis B or C, or HIV infection.\n5. Participants who have received allogeneic HSCT, or autologous HSCT within 12 months.\n6. Patients with active, uncontrolled CNS leukemia will not be eligible.\n7. Any prior systemic MDM2-p53 inhibitor treatment\n8. Any other condition or circumstance that would, in the opinion of the investigator, make the patient unsuitable for participation in the study.\n9. Subject has a history of other malignancies within 2 years prior to study entry, with the exception of:\n\n   * Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast;\n   * Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;\n   * Previous malignancy confined and surgically resected (or treated with other modalities) with curative intention: requires discussion with sponsor.","ALL","18 Years",{"count":242,"type":243},102,"ESTIMATED","INTERVENTIONAL",[246],"PHASE1","Acute myeloid leukemia is a malignant disorder characterized by the rapid, uncontrolled proliferation of malignant clonal hematopoietic stem cells that accumulate as immature, undifferentiated cells (blasts) in the bone marrow and circulation.\n\nAPG-115 is a potent and orally active small-molecule MDM2 inhibitor, it binds to MDM2 protein and shows potent cell growth inhibitory activity in vitro with low nanomolar potencies in a subset of human cancer cell lines. APG-115 has demonstrated its strong antitumor activities with either daily or less frequent dosing-schedules in the acute leukemia xenograft models.\n\nThis is a phase 1b, open-label, three-stages study that will initially evaluate the safety and PK\u002FPD profile of APG-115 as a single agent, followed by a combination of APG-115 + azacytidine or cytarabine in R\u002FR AML or MDS subjects.\n\nPatients will continue treatment for maximally 6 cycles or until progression of disease or unacceptable toxicity is observed or administrative discontinuation whichever occurs first. Patients who continue to be benefit after 6 cycles' treatment will receive additional cycles of treatment until progression of disease, unacceptable toxicity is observed or administrative discontinuation. (As long as it is proven safe).",[249,250],"Acute Myeloid Leukemia (AML)","Myelodysplastic Syndromes (MDS)",[22,252,253],"AML","MDS","2024-10-10",{"date":256,"type":257},"2024-10-15","ACTUAL",{"date":259,"type":257},"2020-07-06",{"date":261,"type":243},"2025-12-31",{"name":5,"class":6},14]